Search Results

You are looking at 81 - 90 of 480 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Targeting Angiogenesis in Advanced Non-Small Cell Lung Cancer

Philip E. Lammers and Leora Horn

randomized phase III trial comparing carboplatin/paclitaxel with or without bevacizumab in 878 patients with recurrent or advanced nonsquamous NSCLC. 9 Improvements in median overall survival (OS), median progression-free survival (PFS), and response rate

Full access

Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer

Kohei Shitara and Atsushi Ohtsu

care was associated with significantly improved OS in patients with disease progression on first-line chemotherapy. 9 Moreover, ramucirumab plus paclitaxel chemotherapy significantly increased OS compared with paclitaxel alone in patients after first

Full access

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

Featured Updates to the NCCN Guidelines

David S. Ettinger, Douglas E. Wood, Charu Aggarwal, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Michael Dobelbower, Scott Gettinger, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Renato G. Martins, Gregory A. Otterson, Sandip P. Patel, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina Gregory, OCN, and Miranda Hughes

combined with bevacizumab/carboplatin/paclitaxel (ABCP) versus bevacizumab/chemotherapy for patients with metastatic nonsquamous NSCLC. 17 Median OS was 19.2 months (95% CI, 17.0–23.8) in the ABCP arm compared with 14.7 months (95% CI, 13.3–16.9) for

Full access

NCCN Guidelines® Updates: Melanoma: Cutaneous

circumstances” to “other recommended”: ► Capecitabine ► Gemcitabine + nab-paclitaxel modified schedule (category 2B) ► Gemcitabine single agent (category 2B) • FOLFIRI (preferred regimen) was removed and replaced with 5-FU ± irinotecan (useful in

Full access

Oncology Research Program

scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck

Full access

Surgery for Ovarian Cancer: Rationale and Guidelines

Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray

carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A Gynecolog Oncology Group study (Abstr 1) . Gynecol Oncol 2003 ; 88 : 156 . 9 Ayhan A Tuncer ZS Tuncer R . Is routine appendectomy beneficial in the

Full access

Epithelial Ovarian Cancer

Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner

disease may also undergo intraperitoneal chemotherapy, although no randomized evidence for stage II disease has been published. 61 , 63 , 64 In women with stage III cancer, survival was increased by 16 months after intraperitoneal therapy using cisplatin/paclitaxel

Full access

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar

endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab, and pertuzumab until disease progression or unacceptable toxicity. The preliminary results after 52 months median follow-up show that median PFS was comparable between

Full access

New Therapies for Ovarian Cancer

David M. O’Malley

ICON7. 1 , 2 A 3-arm trial that enrolled 1,873 patients with newly diagnosed stage III–IV ovarian cancer, GOG-0218 randomly assigned patients 1:1 to carboplatin/paclitaxel followed by placebo maintenance therapy; carboplatin/paclitaxel

Full access

Metastatic Anal Carcinoma: The Role of Radiotherapy

Yi-Jen Chen

) for Anal Carcinoma recommend using 5-FU/cisplatin, carboplatin/paclitaxel, or FOLFOX (5-FU/leucovorin/oxaliplatin) as first-line treatment for MAC. 2 The recently reported randomized, international, multicenter, phase II InterAACT study found that